DoorDash International COO Keith Yandell disposes of 2,183 common shares worth $400,994.27
Bitget2026/10/05 20:10DoorDash International COO Keith Yandell sold 2,183 shares of Class A common stock on Oct. 1, 2026. Sale price USD 183.69 per share. Beneficial ownership stood at 118,505 shares following the transaction. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DoorDash Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001833552-26-000018), on October 05, 2026, and is solely responsible for the information contained therein.
- DoorDash International COO Keith Yandell sold 2,183 shares of Class A common stock on Oct. 1, 2026.
- Sale price USD 183.69 per share.
- Beneficial ownership stood at 118,505 shares following the transaction.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like

Chinese 3D vision AI startup Sensing4D AI submits IPO application to US stock market: plans to raise $35 million and advance embodied intelligence simulation.
Sensing4D AI plans to go public on Nasdaq, aiming to raise $35 million, with a primary focus on 3D reconstruction and embodied intelligence simulation. The company's annual revenue is $29 million.
UK S&P Global Composite PMI improves to 53.1 in October vs. 51.8 expected

Rezera (RZRA.US) submits IPO application: Oral NLRP3 inhibitor pipeline progresses, Phase 3 PAD trial scheduled to begin in 2027
Rezera plans to go public on Nasdaq to raise 100 millions USD. Its oral NLRP3 inhibitor will initiate a Phase III trial for PAD, with data expected in 2028.